← All MEPs

Marcel De Graaff

European Parliament · 🇳🇱 Netherlands · former MEP

Term: from 12 February 2020 to 25 April 2024

Participation in roll-call votes

83 % of the 1,750 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % February 2020 : participation 0 % (0 / 8), presence 0 % (0 / 8) 2020 May 2020 : participation 6 % (3 / 54), presence 6 % (3 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 63 % (12 / 19), presence 63 % (12 / 19) September 2020 : participation 67 % (16 / 24), presence 67 % (16 / 24) October 2020 : participation 97 % (36 / 37), presence 97 % (36 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 100 % (23 / 23), presence 100 % (23 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 100 % (31 / 31), presence 100 % (31 / 31) April 2021 : participation 100 % (81 / 81), presence 100 % (81 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) July 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) September 2021 : participation 95 % (18 / 19), presence 95 % (18 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 0 % (0 / 27), presence 0 % (0 / 27) December 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 100 % (37 / 37), presence 100 % (37 / 37) April 2022 : participation 55 % (12 / 22), presence 55 % (12 / 22) May 2022 : participation 92 % (81 / 88), presence 92 % (81 / 88) June 2022 : participation 93 % (43 / 46), presence 93 % (43 / 46) July 2022 : participation 100 % (31 / 31), presence 100 % (31 / 31) September 2022 : participation 100 % (25 / 25), presence 100 % (25 / 25) October 2022 : participation 0 % (0 / 32), presence 0 % (0 / 32) November 2022 : participation 71 % (27 / 38), presence 71 % (27 / 38) December 2022 : participation 89 % (16 / 18), presence 89 % (16 / 18) January 2023 : participation 100 % (16 / 16), presence 100 % (16 / 16) 2023 February 2023 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2023 : participation 79 % (23 / 29), presence 79 % (23 / 29) April 2023 : participation 100 % (24 / 24), presence 100 % (24 / 24) May 2023 : participation 98 % (91 / 93), presence 98 % (91 / 93) June 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) July 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) September 2023 : participation 100 % (27 / 27), presence 100 % (27 / 27) October 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) November 2023 : participation 40 % (21 / 53), presence 40 % (21 / 53) December 2023 : participation 85 % (34 / 40), presence 85 % (34 / 40) January 2024 : participation 0 % (0 / 49), presence 0 % (0 / 49) 2024 February 2024 : participation 59 % (37 / 63), presence 59 % (37 / 63) March 2024 : participation 86 % (43 / 50), presence 86 % (43 / 50) April 2024 : participation 99 % (210 / 213), presence 99 % (210 / 213)

Their votes

1,750 votes

DateTextResultTheir vote
Financial Activities of the European Investment Bank - annual report 2020 Against
Amendments to Parliament's Rules of Procedure Against
Common system of value added tax: conferral of implementing powers to the Commission to determine the meaning of the terms used in certain provisions Against
2019-2020 Reports on Bosnia and Herzegovina Against
Regulatory fitness, subsidiarity and proportionality - report on Better Law Making 2017, 2018 and 2019 Against
25th anniversary of the International Conference on Population and Development (ICPD25) (Nairobi Summit) Against
Sexual and reproductive health and rights in the EU, in the frame of women’s health Against
Commission’s 2020 Rule of law report Against
Official controls on animals and products of animal origin in order to ensure compliance with the prohibition of certain uses of antimicrobials Against
The role of the EU's development cooperation and humanitarian assistance in addressing the consequences of the COVID-19 pandemic Against
Regulations and general conditions governing the performance of the Ombudsman’s duties Against
The views of Parliament on the ongoing assessment by the Commission and the Council of the national recovery and resilience plans Against
Rule of Law situation in the European Union and the application of the conditionality regulation 2020/2092 Against
The EU's Cybersecurity Strategy for the Digital Decade Against
Future EU financing of the Euranet Plus radio network Against
Promoting gender equality in science, technology, engineering and mathematics (STEM) education and careers Against
European Citizens' Initiative "End the cage age" Against
The situation in Afghanistan Against
Systematic repression in Belarus and its consequences for European security following abductions from an EU civilian plane intercepted by Belarusian authorities Against
Human rights and political situation in Cuba Against
The listing of German NGOs as 'undesirable organisations' by Russia and the detention of Andrei Pivovarov Against
The situation in Sri Lanka, in particular the arrests under the Prevention of Terrorism Act Against
Breach of the UN Convention of the Rights of the Child and the use of minors by the Moroccan authorities in the migratory crisis in Ceuta Against
Commission Implementing Regulation (EU) 2021/745 of 6 May 2021 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances aluminium ammonium sulphate, aluminium silicate, beflubutamid, benthiavalicarb, bifenazate, boscalid, calcium carbonate, captan, carbon dioxide, cymoxanil, dimethomorph, ethephon, extract from tea tree… For
Objection pursuant to Rule 112(2) and (3): Maximum residue limit for imidacloprid For
Meeting the Global Covid-19 challenge: effects of waiver of the WTO TRIPS agreement on Covid-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries Against
The conflict of interest of the Prime Minister of the Czech Republic Against
Transitional provisions of certain machinery fitted with engines in the power range between 56kW and 130kW, and above 300kW in order to address the impact of COVID-19 crisis Against
The gender dimension in Cohesion Policy Against
EU Biodiversity Strategy for 2030: Bringing nature back into our lives Against
Competition policy - annual report 2020 Against
ETIAS consequential amendments: ECRIS-TCN Against
The adequate protection of personal data by the United Kingdom Against
Digital future of Europe: digital single market and use of AI for European consumers Against
New Avenues for Legal Labour Migration Against
Liability of companies for environmental damage Against
European Union Agency for Fundamental Rights: interim report Against
The right of information of the Parliament regarding the ongoing assessment of the national recovery and resilience plans Against
Data Protection Commissioner v Facebook Ireland Limited, Maximillian Schrems (“Schrems II”) - Case C-311/18 Against
Chinese countersanctions on EU entities and MEPs and MPs Against

Rows per page: 20 40 100 200 All